A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. Issue 6 (18th September 2020)

• Record Type: Journal Article
• Authors: Tognetti, Linda; Pianigiani, Elisa; Ierardi, Francesca; Cartocci, Alessandra; Fiorani, Diletta; de Quattro, Marco; Caini, Mauro; Oranges, Teresa; Cinotti, Elisa; Cevenini, Gabriele; Rubegni, Pietro
• Is Part Of: Dermatologic therapy. Volume 33:Issue 6(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-18
• Subjects: high‐resolution video dermoscopy -- infantile hemangiomas -- propranolol treatment; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.14283
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs). Our aim was to assess the morphologic changes of IHs with standard and high‐resolution video dermoscopy (HRVD) from baseline to 18 months either in presence or absence of OP therapy; to investigate if extended anamnestic perinatal data and clinical‐dermoscopic characteristics of the IHs can correlate with therapeutic outcome. We enrolled 94 patients (112 IHs): 58 were treated with OP, 35 (42 IHs) for 6 months ( group 1 ), and 23 (25 IHs) for 12‐months ( group 2 ); 36 (45 IHs) were followed‐up. Clinical‐dermoscopic examinations were performed every 3 months during therapy and follow‐up. Among 67 treated IHs, superficial and deep IHs with homogenous clinical‐dermoscopic aspect developed after the 2 weeks of life achieved the better outcome, stable at 9‐month follow‐up, independently form treatment duration. Under HRVD, glomerular vessels were prevalent at baseline; corckscrew, comma, and linear‐irregular vessels were the prevalent pattern at 1, 3, and 6 months of therapy, respectively. At 12‐month follow‐up, adequate healing was achieved by 96% of IHs in group 2 and by 78% in group 1, showing dotted vessels. Persistent IHs displayed a reticulated aspect and linear irregular vessels, while arborizing vessels characterized relapsed IHs. A 12‐month OP therapy can be considered for newborns presenting with nonhomogenous mixed IHs >3 cm on the perineal area/lower extremities. In conclusion, HRVD allows a real time monitoring of vascular changes in IHs treated with OP and can support physicians in identifying relapses before they become clinically evident.